CBP/p300-IN-22

CBP/p300-IN-22 is a selective CBP/EP300-BRD inhibitor with an IC50 of 4 nM. CBP/p300-IN-22 is highly selective over BRD4 (1) . CBP/p300-IN-22 reduces TNF-α-induced cytokine expression and subsequent immune cell recruitment by inhibiting NF-κB signaling, and has anticancer activity. CBP/p300-IN-22 can be used for the research of rheumatoid arthritis (RA) and other TNF-α-mediated inflammatory conditions[1].

C25H20N6O3

452.46

CC1=CC2=C(NC(C3=CC(C4=NN(C)C=C4)=CC(NC(C5=CC=CO5)=O)=C3)=O)C=CC=C2N=N1

Epigenetic Reader Domain; Histone Acetyltransferase; NF-κB

BRD4; CBP/p300

Room temperature